ArticleResearch and practice in thrombosis and haemostasis2026
Alpha-1 antitrypsin deficiency associated with increased risk of venous thromboembolism: a nationwide cohort study in Denmark.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mechanistic investigations suggest that alpha-1 antitrypsin may influence hemostatic processes; however, whether alpha-1 antitrypsin deficiency is associated with an elevated risk of venous thromboembolism is unclear. Objectives: We tested whether alpha-1 antitrypsin deficiency is associated with venous thromboembolisms in 2 large independent cohorts. Methods: In a nationwide nested cohort of 3046 individuals with alpha-1 antitrypsin deficiency and 29,742 controls without it matched for sex, age, and municipality, we recorded admissions and deaths due to pulmonary embolism and admissions due to deep vein thrombosis and venous thromboembolism during a median follow-up time of up to 61 years. Sixteen thousand seven hundred sixty-eight individuals being heterozygous for alpha-1 antitrypsin deficiency and 415,208 controls from the UK Biobank were used as a confirmatory cohort. Results: Compared with controls, individuals with alpha-1 antitrypsin deficiency had increased risks of pulmonary embolism (adjusted hazard ratio, 3.28, 95% CI, 2.73-3.94), pulmonary embolism-specific mortality (2.83; 95% CI, 1.65-4.84), deep vein thrombosis (1.85; 95% CI, 1.53-2.25), and venous thromboembolism (2.43; 95% CI, 2.12-2.80). Individuals with vs without alpha-1 antitrypsin deficiency also had an increased use of the direct oral anticoagulants apixaban (1.83; 95% CI, 1.30-2.56) and rivaroxaban (1.49; 95% CI, 1.11-1.99). The association between the heterozygosity of alpha-1 antitrypsin deficiency and pulmonary embolism, deep vein thrombosis, and venous thromboembolism was confirmed in the UK Biobank. Moreover, hospitalization rates for these conditions were higher in individuals heterozygous for alpha-1 antitrypsin deficiency compared with those in controls. Conclusion: Alpha-1 antitrypsin deficiency was associated with increased risks of pulmonary embolism, deep vein thrombosis, and venous thromboembolism in 2 independent populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.